Vertex raised Orkambi’s price from $251,000 per year to about $273,000 annually, representing a 5 percent increase.
The drug is widely available to patients through insurance coverage, and Vertex does not anticipate the price hike to affect patients’ out-of-pocket costs, a company spokeswoman told Boston Business Journal.
Orkambi produced $980 million in sales last year.
More articles on supply chain:
Britain looks to work with EU on drug regulation post-Brexit
Novo Nordisk recalls insulin pen cartridge holders
Pharma looks to AI for streamlined drug development
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
